Teva Pharmaceutical Industries Ltd (NYSE:TEVA)‘s stock had its “neutral” rating reiterated by investment analysts at BTIG Research in a research note issued to investors on Thursday.
TEVA has been the topic of a number of other research reports. Gabelli reissued a “buy” rating on shares of Teva Pharmaceutical Industries in a report on Monday, January 9th. Royal Bank of Canada set a $42.00 price objective on Teva Pharmaceutical Industries and gave the stock a “buy” rating in a report on Monday, January 9th. Guggenheim reaffirmed a “buy” rating and set a $80.00 price objective on shares of Teva Pharmaceutical Industries in a report on Friday, December 23rd. Deutsche Bank AG reaffirmed a “buy” rating and set a $54.00 price objective on shares of Teva Pharmaceutical Industries in a report on Wednesday, December 7th. Finally, Maxim Group decreased their target price on Teva Pharmaceutical Industries from $52.00 to $49.00 and set a “buy” rating on the stock in a research report on Tuesday, January 3rd. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $45.14.
Teva Pharmaceutical Industries (NYSE:TEVA) traded up 1.20% during midday trading on Thursday, hitting $31.13. 6,457,334 shares of the stock traded hands. Teva Pharmaceutical Industries has a 52-week low of $30.57 and a 52-week high of $57.52. The company has a market cap of $31.60 billion, a price-to-earnings ratio of 444.71 and a beta of 0.58. The firm’s 50-day moving average is $32.75 and its 200-day moving average is $36.56. Teva Pharmaceutical Industries also saw some unusual options trading on Thursday. Stock investors acquired 422 put options on the company. This represents an increase of approximately 111% compared to the typical volume of 200 put options.
Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Monday, February 13th. The company reported $1.38 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.36 by $0.02. Teva Pharmaceutical Industries had a return on equity of 17.46% and a net margin of 1.50%. The company earned $6.25 billion during the quarter, compared to analysts’ expectations of $6.26 billion. During the same quarter in the previous year, the business earned $1.32 earnings per share. The firm’s revenue for the quarter was up 33.0% on a year-over-year basis. Analysts predict that Teva Pharmaceutical Industries will post $4.82 EPS for the current year.
A number of large investors have recently modified their holdings of the stock. Rothschild Investment Corp IL increased its position in Teva Pharmaceutical Industries by 1.5% in the third quarter. Rothschild Investment Corp IL now owns 17,393 shares of the company’s stock worth $800,000 after buying an additional 263 shares in the last quarter. Bank of Montreal Can increased its position in Teva Pharmaceutical Industries by 10.3% in the third quarter. Bank of Montreal Can now owns 412,911 shares of the company’s stock worth $18,998,000 after buying an additional 38,461 shares in the last quarter. Hayek Kallen Investment Management increased its position in Teva Pharmaceutical Industries by 2.0% in the third quarter. Hayek Kallen Investment Management now owns 71,867 shares of the company’s stock worth $3,307,000 after buying an additional 1,381 shares in the last quarter. Trust Co. of Vermont increased its position in Teva Pharmaceutical Industries by 7.9% in the third quarter. Trust Co. of Vermont now owns 15,005 shares of the company’s stock worth $691,000 after buying an additional 1,105 shares in the last quarter. Finally, Heritage Investors Management Corp increased its position in Teva Pharmaceutical Industries by 10.2% in the third quarter. Heritage Investors Management Corp now owns 161,484 shares of the company’s stock worth $7,430,000 after buying an additional 14,922 shares in the last quarter. Hedge funds and other institutional investors own 55.03% of the company’s stock.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd and related companies with MarketBeat.com's FREE daily email newsletter.